Evaluation of immunocompetency in juvenile laryngeal papillomatosis

D. Perrick, Betty Beasley Wray, M. S. Leffell, J. Douglas Harmon, E. S. Porubsky

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The morbidity form juvenile laryngeal papillomatosis (JLP), a disease process characterized by recurrent growth of multiple epithelial papillomas, has greatly improved with the advent of immunomodulating agents used in combination with the surgical approach of CO2 laser vaporization. In prospectively evaluating the immunologic status of four pediatric patients with this disorder, one patient repeatedly demonstrated IgG2 subclass deficiency. One of two children found to have subnormal functional natural killer (NK) activity received thrice weekly intramuscular administration of 3,000,000 units/m2 body surface area of human leukocyte (alpha) interferon (IFN). Natural killer function normalizd, but therapy was discontinued after 4 months; however, no clinical benefits from IFN administration were observed. Further in vitro evaluation of NK function and lymphokine production is needed, in order eventually to offer more effective immunomodulating agents to such patients. A brief review of the literature concerning JLP is also presented.

Original languageEnglish (US)
Pages (from-to)69-72
Number of pages4
JournalAnnals of Allergy
Volume65
Issue number1
StatePublished - Jan 1 1990

Fingerprint

Interferon-alpha
Gas Lasers
Lymphokines
Body Surface Area
Papilloma
Laser Therapy
Interferons
Immunoglobulin G
Pediatrics
Morbidity
Growth
Laryngeal papillomatosis
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Perrick, D., Wray, B. B., Leffell, M. S., Douglas Harmon, J., & Porubsky, E. S. (1990). Evaluation of immunocompetency in juvenile laryngeal papillomatosis. Annals of Allergy, 65(1), 69-72.

Evaluation of immunocompetency in juvenile laryngeal papillomatosis. / Perrick, D.; Wray, Betty Beasley; Leffell, M. S.; Douglas Harmon, J.; Porubsky, E. S.

In: Annals of Allergy, Vol. 65, No. 1, 01.01.1990, p. 69-72.

Research output: Contribution to journalArticle

Perrick, D, Wray, BB, Leffell, MS, Douglas Harmon, J & Porubsky, ES 1990, 'Evaluation of immunocompetency in juvenile laryngeal papillomatosis', Annals of Allergy, vol. 65, no. 1, pp. 69-72.
Perrick D, Wray BB, Leffell MS, Douglas Harmon J, Porubsky ES. Evaluation of immunocompetency in juvenile laryngeal papillomatosis. Annals of Allergy. 1990 Jan 1;65(1):69-72.
Perrick, D. ; Wray, Betty Beasley ; Leffell, M. S. ; Douglas Harmon, J. ; Porubsky, E. S. / Evaluation of immunocompetency in juvenile laryngeal papillomatosis. In: Annals of Allergy. 1990 ; Vol. 65, No. 1. pp. 69-72.
@article{a9070863f5814b2983e1c146d1319ba3,
title = "Evaluation of immunocompetency in juvenile laryngeal papillomatosis",
abstract = "The morbidity form juvenile laryngeal papillomatosis (JLP), a disease process characterized by recurrent growth of multiple epithelial papillomas, has greatly improved with the advent of immunomodulating agents used in combination with the surgical approach of CO2 laser vaporization. In prospectively evaluating the immunologic status of four pediatric patients with this disorder, one patient repeatedly demonstrated IgG2 subclass deficiency. One of two children found to have subnormal functional natural killer (NK) activity received thrice weekly intramuscular administration of 3,000,000 units/m2 body surface area of human leukocyte (alpha) interferon (IFN). Natural killer function normalizd, but therapy was discontinued after 4 months; however, no clinical benefits from IFN administration were observed. Further in vitro evaluation of NK function and lymphokine production is needed, in order eventually to offer more effective immunomodulating agents to such patients. A brief review of the literature concerning JLP is also presented.",
author = "D. Perrick and Wray, {Betty Beasley} and Leffell, {M. S.} and {Douglas Harmon}, J. and Porubsky, {E. S.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "65",
pages = "69--72",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "1",

}

TY - JOUR

T1 - Evaluation of immunocompetency in juvenile laryngeal papillomatosis

AU - Perrick, D.

AU - Wray, Betty Beasley

AU - Leffell, M. S.

AU - Douglas Harmon, J.

AU - Porubsky, E. S.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - The morbidity form juvenile laryngeal papillomatosis (JLP), a disease process characterized by recurrent growth of multiple epithelial papillomas, has greatly improved with the advent of immunomodulating agents used in combination with the surgical approach of CO2 laser vaporization. In prospectively evaluating the immunologic status of four pediatric patients with this disorder, one patient repeatedly demonstrated IgG2 subclass deficiency. One of two children found to have subnormal functional natural killer (NK) activity received thrice weekly intramuscular administration of 3,000,000 units/m2 body surface area of human leukocyte (alpha) interferon (IFN). Natural killer function normalizd, but therapy was discontinued after 4 months; however, no clinical benefits from IFN administration were observed. Further in vitro evaluation of NK function and lymphokine production is needed, in order eventually to offer more effective immunomodulating agents to such patients. A brief review of the literature concerning JLP is also presented.

AB - The morbidity form juvenile laryngeal papillomatosis (JLP), a disease process characterized by recurrent growth of multiple epithelial papillomas, has greatly improved with the advent of immunomodulating agents used in combination with the surgical approach of CO2 laser vaporization. In prospectively evaluating the immunologic status of four pediatric patients with this disorder, one patient repeatedly demonstrated IgG2 subclass deficiency. One of two children found to have subnormal functional natural killer (NK) activity received thrice weekly intramuscular administration of 3,000,000 units/m2 body surface area of human leukocyte (alpha) interferon (IFN). Natural killer function normalizd, but therapy was discontinued after 4 months; however, no clinical benefits from IFN administration were observed. Further in vitro evaluation of NK function and lymphokine production is needed, in order eventually to offer more effective immunomodulating agents to such patients. A brief review of the literature concerning JLP is also presented.

UR - http://www.scopus.com/inward/record.url?scp=0025303541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025303541&partnerID=8YFLogxK

M3 - Article

C2 - 2368934

AN - SCOPUS:0025303541

VL - 65

SP - 69

EP - 72

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 1

ER -